HDAC9 and Alzheimer disease: Selective inhibitors such as tubastatin A (targeting HDAC6) and RGFP966 (targeting HDAC3) exhibit isoform-specific activity, supporting the therapeutic potential of both broad-spectrum and targeted HDAC modulation in AD [28].